Sanofi-Aventis Gets Priority Review For Second-Generation Atrial Fib Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval could come in early 2009 for Cordarone successor Multaq.
You may also be interested in...
Dronedarone advisory committee review
FDA's Cardiovascular and Renal Drugs Advisory Committee is meeting March 18 to discuss Sanofi-Aventis' NDA for Multaq (dronedarone) 400 mg oral tablets, proposed for patients with a history of, or current, atrial fibrillation or atrial flutter, for the reduction of the risk of cardiovascular hospitalization or death. The NDA is based on the recently published ATHENA study (1"The Pink Sheet" DAILY, Aug. 11, 2008)
Dronedarone advisory committee review
FDA's Cardiovascular and Renal Drugs Advisory Committee is meeting March 18 to discuss Sanofi-Aventis' NDA for Multaq (dronedarone) 400 mg oral tablets, proposed for patients with a history of, or current, atrial fibrillation or atrial flutter, for the reduction of the risk of cardiovascular hospitalization or death. The NDA is based on the recently published ATHENA study (1"The Pink Sheet" DAILY, Aug. 11, 2008)
Sanofi-Aventis Pares Pipeline, Ditches Antidepressant Amibegron
In light of clinical setbacks and a broader overhaul, Sanofi-Aventis has ended some once-promising advanced development programs, while the fates of others hang in the balance, pending study results and strategic reviews